BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/18/2022 8:29:59 AM | Browse: 322 | Download: 880
 |
Received |
|
2022-07-02 18:19 |
|
Peer-Review Started |
|
2022-07-02 18:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-01 00:37 |
|
Revised |
|
2022-09-24 20:39 |
|
Second Decision |
|
2022-10-10 03:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-10-10 14:58 |
|
Articles in Press |
|
2022-10-10 14:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-10-12 02:36 |
|
Publish the Manuscript Online |
|
2022-10-18 08:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alexa R Weingarden, John Gubatan, Sundeep Singh, Tatiana Clorice Balabanis, Akshar Patel, Arpita Sharma and Aida Habtezion |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alexa R Weingarden, MD, PhD, Academic Fellow, Consultant Physician-Scientist, Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, United States. aweingar@stanford.edu |
| Key Words |
Immune checkpoint inhibitors; Immune checkpoint inhibitor-mediated colitis; Immune-related adverse events; Overall survival |
| Core Tip |
Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. We sought to determine the association of IMC with overall survival (OS) and progression-free survival (PFS) among cancer patients treated with ICI and identify clinical predictors of IMC. We performed a retrospective case-control study including 64 ICI users who developed IMC. In multivariate logistic regression analysis, IMC was significantly associated with a higher OS but not PFS. IMC was significantly associated with OS greater than 12 mo. Vitamin D supplementation was associated with increased risk of IMC. |
| Publish Date |
2022-10-18 08:29 |
| Citation |
Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. World J Gastroenterol 2022; 28(39): 5750-5763 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i39/5750.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i39.5750 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
